Beijing, China.-Cuban People’s Power National Assembly President (ANPP), Esteban Lazo Hernandez, has reviewed here today the progress and exchanges in biotechnology with the Chinese side, a relevant pillar in the ties between both countries.

During a visit carried out today to the Cuban-Chinese joint venture Biotech Pharmaceuticals Co.LTD, located in the Special Development Zone of this capital, dedicated to the development, production and marketing of monoclonal antibodies for the treatment of cancer, the parliamentary leader of the Caribbean island was received by the directive and personnel from both territories working in that company.

David Curbelo, the company’s vice president for the Cuban side, explained Lazo the benefits of the company -which- with almost one decade of productive experience, welcomes 300 workers, included 14 Cuban experts.

He acknowledged that biotechnology is a branch in which Cuba and China have made significant progress in recent years and in which they have maintained a close cooperation with fruitful results of cooperation, generating great benefits and knowledge for the peoples of the two nations.

Lazo stressed the importance of saving hundreds of thousands of lives with the drugs this corporation produces, including those aimed at treating lung cancer.

The high-technology joint venture registers its last renewal in 2015 valid until 2018, with an annual sales operation of 360 million yuan (about $51.4 million USD) in China, and a contribution of dividends to the Caribbean country of more than $8 million USD per year (2012-2015).

The ANPP president arrived in this capital last night in an official visit on an invitation by the maximum legislator of China, Zhang Dejiang.

Lazo plans to comply with a working agenda until Friday, June 23rd, that includes meetings with other senior leaders of this country to review strategies aimed at increasing cooperation between both parliamentary bodies as well as to push forward the bilateral ties.